40428-86-2

Basic information

• Product Name: adenine, monosodium salt
• Synonyms: adenine, monosodium salt;1-Sodio-1H-purin-6-amine
• CAS NO: 40428-86-2
• Molecular Formula: C₅H₄N₅*Na
• Molecular Weight: 157.10853
• EINECS: 254-916-2
• Mol File: 40428-86-2.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: adenine, monosodium salt(CAS DataBase Reference)
• NIST Chemistry Reference: adenine, monosodium salt(40428-86-2)
• EPA Substance Registry System: adenine, monosodium salt(40428-86-2)

Safety Data

• Hazardous Substances Data: 40428-86-2(Hazardous Substances Data)

Upstream product

• 66224-66-6 adenine 

Downstream Products

• 744261-83-4 Benzoic acid 3-(6-amino-purin-9-ylmethyl)-phenyl ester 
• 68220-23-5 3-(2-chloro-6-fluorobenzyl)-3H-purin-6-ylamine 
• 55779-18-5 9-(2-chloro-6-fluorobenzyl)adenine 
• 4261-14-7 9-benzyl-9H-purin-6-ylamine 
• 3691-50-7 7-benzyladenine 
• 7280-81-1 3-benzyladenine 
• 121409-45-8 2'-deoxy-3',5'-di-O-(4-methylbenzoyl)adenosine 
• 121409-44-7 9-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythro-pentofuranosyl) adenine 
• 19255-48-2 9-(2-chloroethyl)adenine 
• 19255-49-3 9-(3-chloropropyl)-9H-purin-6-amine 
• 84856-98-4 6-(Adenin-9-yl)-6-deoxy-3,5-di-O-isopropylidene-α-D-glucofuranose 
• 25477-96-7 ethyl 2-(9H-adenin-9-yl)acetate 
• 183197-54-8 [2-(6-Amino-purin-9-yl)-1-phenoxy-ethoxymethyl]-phosphonic acid diisopropyl ester 
• 205382-53-2 (4aR,7S,8S,8aS)-8-(6-Amino-purin-9-yl)-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ol 

Relevant articles and documents

Towards a Molecular Understanding of Cation-Anion Interactions and Self-aggregation of Adeninate Salts in DMSO by NMR and UV Spectroscopy and Crystallography

Rare anionic forms of nucleic acids play a significant biological role and lead to spontaneous mutations and replication and translational errors. There is a lack of information surrounding the stability and reactivity of these forms. Ion pairs of mono-sodium and -potassium salts of adenine exist in DMSO solution with possible cation coordination sites at the N1, N7 and N9 atoms of the purine ring. At increasing concentrations π-π stacked dimers are the predominant species of aggregates followed by higher order aggregation governed by coordination to metal cations in which the type of counter ion present has a central role in the aggregate formation.

PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES

Nucleoside chemical compounds, which interact with specific structures of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) are disclosed. The compounds interfere with the activities of telomerase and reverse transcriptase, and are useful as antivirals, antibacterials and anticancer agents. Methods of treating or preventing cancers in patients involving administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of the reverse transcriptases (RTs) expressed in cells of the patients are also disclosed. Method of using nucleoside analogs and other inhibitors of RTs in conjunction with DNA damaging agents such as genotoxic agents or radiation or photodynamic therapy or combinations these for the treatment of various cancers are also disclosed.

2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents

Compounds which are active against viruses have the following Formulas: wherein B is a purine or pyrimidine heterocyclic ring and is preferably selected from the group consisting of 6-aminopurine (adenine), 2,6-diaminopurine, 2-amino-6-azidopurine, 2-amino-6-cyclopropylaminopurine, 6-hydroxypurine (hypoxanthine), 2-amino-6-halo substituted purines, 2-amino-6-alkoxy substituted purines, 2-amino-6-hydroxypurine (guanine), 3-deazapurines, 7-deaza-purines, 8-azapurines, cytosine, 5-halo substituted cytosines, 5-alkyl substituted cytosines, thymine, uracil and 6-azapyrimidines; X is O; and, R1 and R2 are alkyl or aryl groups. The compounds of the present invention also include the R- and S-enantiomers of the above compounds. The R1X and/or R2X can also be amino acid residues with X as NH.